Genentech Giredestrant Combo Improved PFS in Advanced Breast Cancer: evERA Data
Genentech announced that detailed results from the evERA Breast Cancer study showed that investigational giredestrant in combination with everolimus significantly improved progression-free survival versus standard endocrine therapy. The data were published in The New England Journal of Medicine.